secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker NGVC CIK 0001547459
earnings confidence high sentiment positive materiality 0.50

Natural Grocers Q2: net sales +0.5% to $337.4M; EPS $0.58; Adj. EBITDA +4% to $27.4M

Natural Grocers by Vitamin Cottage, Inc.

2026-Q2 EPS reported $1.07 revenue$672,955,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001437749-26-015580
form_type
8-K
ticker
NGVC
cik
0001547459
company_name
Natural Grocers by Vitamin Cottage, Inc.
filed_at
2026-05-07T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.451134+00:00
generated_at
2026-05-14T21:40:16.546020+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
positive
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001437749-26-015580
json_url
https://secwatch.observer/filing/0001437749-26-015580.json
markdown_url
https://secwatch.observer/filing/0001437749-26-015580.md
text_url
https://secwatch.observer/filing/0001437749-26-015580.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1547459/000143774926015580/0001437749-26-015580-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1547459/000143774926015580/ngvc20260505_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

7a2219abf14326885957ce3ec3290dd714fa54e5

Natural Grocers by Vitamin Cottage, Inc. reported second quarter of fiscal 2026 ended March 31, 2026 results: revenue $337.4 million, net income $13.4 million, EPS $0.58.

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

SEC 8-K Item 2.02 confidence 0.95 SEC evidence

Comparable filings

EXPI

eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)

eXp World Holdings, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash

Filing page SEC filing

HAIN

Hain Celestial reports Q3 FY2026 earnings; detailed figures not included in filing excerpt

HAIN CELESTIAL GROUP INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

On May 11, 2026, The Hain Celestial Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended March 31, 2026.

Filing page SEC filing

HRTX

Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed

HERON THERAPEUTICS, INC. /DE/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Filing page SEC filing

XGN

Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed

EXAGEN INC. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per

Filing page SEC filing

CGBD

Carlyle Secured Lending Q1 NII $0.36/sh; NAV down 2.3% to $15.89; declares $0.35 dividend

Carlyle Secured Lending, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

For the first quarter of 2026, we reported $0.36 per common share of Net Investment Income and Adjusted Net Investment Income, a non-GAAP financial measure described below.

Filing page SEC filing

OPAL

OPAL Fuels Q1 2026 Adj EBITDA $16.7M, net loss $(5.6)M; revenue down 14% YoY

OPAL Fuels Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

Revenue for the three months ended March 31, 2026 and 2025, was $73.4 million and $85.4 million respectively, a decrease of (14)%, compared to the same period last year. 1 • Net (loss) income for the three months ended March 31, 2026 was $(5.6) million, compared to $1.3 million in the same period last year. • Basic and diluted net loss per share attributable to Class A common shareholders for the three months ended months ended March 31, 2026 were $(0.09) compared to $(0.01) in the comparable period last year.

Filing page SEC filing

OLPX

Olaplex Q1 net sales up 2.5% to $99.4M but swings to net loss of $5.3M; adjusted EBITDA falls 26.1%

OLAPLEX HOLDINGS, INC. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

team for their continued dedication and commitment to our transformation." For the first quarter of 2026 compared to the first quarter of 2025: • Net sal es increased 2.5% to $99.4 million; ◦ By channel: ▪ Specialty Retail decreased 13.3% to $33.4 million; ▪ Professional increased 12.3% to $38.8 million; ▪ Direct-To-Consumer increased 13.8% to $27.2 million; ◦ Net

Filing page SEC filing

FEMY

Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026

FEMASYS INC May 8, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

for its second quarter of fiscal 2026 ended March 31, 2026. Highlights for Second Quarter Fiscal 2026 Compared to Second Quarter Fiscal 2025 ● Net sales increased 0.5% to $337.4 million; ● Daily average comparable store sales increased 0.5%, and 9.4% on a two-year basis; ● Net income increased 2.5% to $13.4 million, with diluted earnings per share of $0.58; ●

Comparable filing

addressing critical unmet needs with safe, technologically advanced products.” Financial Results for Quarter Ended March 31, 2026 • Sales increased by $83,625, or 24.5%, to $424,889 in 2026 from $341,264 in 2025, primarily due to sales of FemBloc. • Research and development expenses decreased by $1,659,071, or 55.9%, to $1,309,401 in 2026 compared to

Filing page SEC filing

Source: SEC EDGAR
accession 0001437749-26-015580
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.